SEMAFO: Early Warning News Release
MONTREAL, Feb. 09, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has subscribed to 33,333,333 common shares of Savary Gold Corp. (TSXV:SCA) ("Savary") at a price of $0.06 per common share for an aggregate subscription price of approximately $2,000,000 pursuant to a private placement financing of common shares of Savary previously announced by Savary on January 29, 2018 (the "Financing").
Prior to completion of the Financing, SEMAFO did not hold any shares or convertible securities of Savary. Following closing of the transaction, SEMAFO holds a total of 33,333,333 common shares of Savary, approximately 15.5% of Savary's issued and outstanding common shares on a non-diluted basis.
SEMAFO acquired the common shares described in this press release for investment purposes and in accordance with applicable securities laws.
Pursuant to the subscription agreement between Savary and SEMAFO, SEMAFO shall have the right to appoint one director to Savary's Board of directors or to instruct Savary to insert in its next proxy circular a SEMAFO nominee for election at Savary's next shareholder meeting. SEMAFO shall keep this right as long as it continues to hold no less than 10% of Savary issued and outstanding shares on a non-diluted basis.
The closing of the private placement of common shares remains subject to final approval of the TSX Venture Exchange. The common shares issues are subject to a four-month and one-day hold period in accordance with applicable Canadian securities laws, from the date of closing.
A copy of the early warning report to be filed by SEMAFO in connection with the Private Placement described above will be available on SEDAR under Savary's profile.
SEMAFO is a Canadian-based mining company with gold production and exploration activities in West Africa. The Corporation operates the Mana Mine in Burkina Faso, which includes the high-grade satellite deposit of Siou, and is targeting production start-up of the Boungou Mine in the third quarter of 2018. SEMAFO's strategic focus is to maximize shareholder value by effectively managing its existing assets as well as pursuing organic and strategic growth opportunities.
The information in this release is subject to the disclosure requirements of SEMAFO under the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. This information was publicly communicated on February 9, 2018 at 10:00 a.m., Eastern Standard Time.
For more information, contact
Vice-President, Corporate Development & Investor Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SEMAFO Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Validated with Microsoft Skype for Business, Patton Delivers Cloud-Powered Integration19.3.2019 05:00:00 CET | Pressemelding
SmartNode ™ VoIP gateways and eSBCs, validated by TekVizion, integrate legacy telephony, ALL-IP communications — or both concurrently — with Skype for Business SmartNode ™ VoIP… More than Just Talk! GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Patton—US-based enabling solutions provider for unified communications (UC), UC-as-a-service (UCaaS) and Cloud—now announces all SmartNode VoIP products version 3.X—including Virtual SmartNode (vSN)—are validated for interoperability with Skype for Business (SfB). SmartNode products are validated by TekVizion, a Microsoft-certified lab, in the SBC and enhanced gateway categories, and are forward compatible with Microsoft Teams. >>Certificate of Validation: Patton SBC/Gateway 3.X Patton Cloud edge orchestration service makes it extra easy to activate, configure and manage the SmartNode-enabled connection with on-premise or hosted Skype for Business. In addition to enabling enterprise transition to ALL-IP using SfB, Patton’s VoIP CPE produ
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CET | Pressemelding
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CET | Pressemelding
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera
Mattson Technology Announces Hydrilis™, a Unique High-Productivity Vacuum Wafer Process Platform18.3.2019 17:00:00 CET | Pressemelding
– Up to 4 process chambers and 8 wafer processing stations – – Smallest footprint, highest throughput platform – – Enables any process chamber, any position configuration flexibility – FREMONT, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Mattson Technology, Inc., a leading supplier of advanced process equipment used to manufacture semiconductors, introduces Hydrilis™, the industry’s highest productivity density vacuum transfer platform featuring high throughput on the smallest footprint. The Hydrilis platform can be configured with up to 4 process chambers, or 8 processing stations, for parallel or sequential wafer processing. Any of the paradigmE® family plasma etch process chambers, Suprema® family plasma photoresist strip and hard-mask removal process chambers, Novyka™ family surface treatment process chambers and Novyka family selective chemical dry etch process chambers can all be integrated on the Hydrilis platform. “Throughput per unit area of fab space is one of the key criteria
Minerva Neurosciences to Host Webcast Event on Schizophrenia18.3.2019 13:30:00 CET | Pressemelding
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader. Discussions will feature the following speakers
Infovista Enhances Ipanema SD-WAN with Nextgen Application Intelligence+ and Cloud-Native Orchestration18.3.2019 13:00:00 CET | Pressemelding
PARIS and ASHBURN, Va., March 18, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new cloud-native management and control with next-generation Application Intelligence+ for Ipanema SD-WAN, delivering unmatched application performance across any WAN. Tweet This: Infovista enhances Ipanema SD-WAN with nextgen Application Intelligence+ and cloud native orchestration: https://bit.ly/2ULcKLW #SmarterSDWAN The enterprise network has become the central nervous system of modern digital businesses, and SD-WAN is enabling this digital transformation. Infovista’s Ipanema SD-WAN with new cloud-native management and control of applications tightly combines session-based routing and dynamic path selection of the underlay network with an overlay of deep application visibility and dynamic control of the quality of experience for business-critical applications. Additionally, Ipanema automatically understands application delivery requirements and maintains a